MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric A β25-35 -induced anxiety and cognitive deficits in a mouse model.
CONCLUSIONS: These results reveal MGCD0103 could be a potential therapeutic agent against AD.
PMID: 29978554 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - Category: Neuroscience Authors: Huang HJ, Huang HY, Hsieh-Li HM Tags: CNS Neurosci Ther Source Type: research
More News: Alzheimer's | Anxiety | Brain | Liver | Neurology | Neuroscience | Toxicology | Urology & Nephrology